Dr Reddys unveils generic version of Vasostrict vials in US
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Hyderabad: Drugmaker, Dr. Reddy's Laboratories Ltd., has recently announced the launch of the company's authorized generic version of Par Pharmaceutical's VASOSTRICT (vasopressin injection, USP) Vials in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
Read also : Dr Reddys, Prestige BioPharma ink pact for Trastuzumab biosimilar commercialization in select countries
The Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin (also known as antidiuretic hormone) plays a crucial role in regulating the circadian rhythm — the periods of sleepiness and wakefulness in a 24-hour cycle which is regulated by Hypothalamus. Vasopressin also helps in maintaining the body's internal temperature, its blood volume, and the proper flow of urine from the kidneys.
Dr. Reddy's Vasopressin Injection, USP, is supplied in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL.
Vasostrict is a trademark of Par Pharmaceutical Inc. The company offers an extensive range of prescription products across various therapeutic categories.
The VASOSTRICT brand market had U.S. sales of approximately $878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health*.
Read also: Dr Reddy's Labs bags DCGI emergency use nod for single dose Sputnik Light in India
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddys in S&P Global Sustainability Yearbook for 2nd Year
